CLINICAL_TRIALS
trial_result
· 2022-11-08
Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis [Phase 3]
Summary
Phase 3 trial of baricitinib in moderate to severe atopic dermatitis was terminated; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: TERMINATED | Results posted: 2022-11-08